Genetic Optimization of Liver Cancer Therapy: A Patient-Derived Primary Cancer Cell- Based Model Patricia Munoz-Garrido, Jesper B. Andersen Gastroenterology Volume 152, Issue 1, Pages 19-21 (January 2017) DOI: 10.1053/j.gastro.2016.11.030 Copyright © 2017 AGA Institute Terms and Conditions
Figure 1 Overview of the patient-derived cell line-based model. The schematic illustrates (A) intertumor heterogeneity and phylogenetic tree modeling of each patient, (B) intratumor heterogeneity (ITH) in human HCC and the patient-derived primary cancer cell (PDPC) culture model. (C) Focusing on a particular case the authors report that drug response is strictly dependent according to the expression of FGF19 in each tumor clone. This highlights the need for combination therapy and essential requirement for integration of genomic data prior to therapeutic decisions. Gastroenterology 2017 152, 19-21DOI: (10.1053/j.gastro.2016.11.030) Copyright © 2017 AGA Institute Terms and Conditions